Abstract：Objective To study the clinical effect of recombinant human erythropoietin (EPO) combined with gangliosides on neonatal hypoxic-ischemic encephalopathy (HIE). Methods A total of 80 cases of children with HIE were selected and divided into the control group (40 cases) and the study group (40 cases) in Huaibei Miner General Hospital from January 2016 to June 2017 according to the treatment. The control group was treated with Monosialoteterahexosyl ganglioside (GM-1). the study group was treated with GM-1 and recombinant human EPO, and the treatment lasted for 10-14 day. The NBNA scale was used to evaluate the neurobehavior on the 7th, 14th, and 28th day after birth. The CDCC and Gesell scales were used to evaluate the intellectual development and developmental quotients of the two groups at 3 months and 6 months of age, respectively, and the therapeutic efficacy and prognosis of the two groups were evaluated. Results There was no significant difference in NBNA scores between the two groups 7 d after birth (P > 0.05). The NBNA scores of the study group were significantly higher on the 14th and 28th day after birth than in the control group (P < 0.05). MDI, PDI scores and Gesell scores at 6 months of age in both groups were significantly higher than those at 3 months of age (P < 0.05). The MDI, PDI scores and Gesell scores of the study group at 3 months and 6 months of age were significantly higher than those of the control group (P < 0.05). The total effective rate in the study group was 92.50%, which was significantly higher than the 75.00% in the control group (P < 0.05). There was no significant difference in sequelae and prognosis between the two groups (P > 0.05). Conclusion The combination therapy of GM-1 and recombinant human EPO can significantly improve the neurobehavioral and central nervous system function in children with HIE. The treatment method has good clinical efficacy, high safety, and has great clinical application value.
2018, Vol. 15 
京公网安备 11010502046598号